医学
彭布罗利珠单抗
卡铂
危险系数
吉西他滨
肿瘤科
化疗
内科学
杜瓦卢马布
癌症
顺铂
置信区间
免疫疗法
作者
Thomas Powles,Begoña P. Valderrama,Shilpa Gupta,Jens Bedke,Eiji Kikuchi,Jean Hoffman‐Censits,Gopa Iyer,Christof Vulsteke,Se Hoon Park,Sang Joon Shin,Daniel Castellano,Giuseppe Fornarini,Jian‐Ri Li,Mahmut Gümüş,Nataliya Mar,Yohann Loriot,Aude Fléchon,Ignacio Durán,Alexandra Drakaki,Sujata Narayanan
标识
DOI：10.1056/nejmoa2312117
摘要
Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
嘻嘻哈哈
GingerF
让我多睡会吧
ho
Criminology34
自然的清涟
浮游
gkads
1351567822
二小儿
tuanheqi
脑洞疼
嘿嘿
Lucas
LPPQBB
BBBBBlue先森
Simon
蛙蛙
siri
山亭
遇上就这样吧
kentonchow
Yini
刘海清
皖公网安备34019202002308
